• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Evaluation of a lipid management pathway within a local cardiac rehabilitation service.当地心脏康复服务中脂质管理途径的评估。
Br J Cardiol. 2022 Nov 9;29(4):34. doi: 10.5837/bjc.2022.034. eCollection 2022.
2
[Status of cholesterol goal attainment for the primary and secondary prevention of atherosclerotic cardiovascular disease in dyslipidemia patients receiving lipid-lowering therapy: DYSIS-China subgroup analysis].[接受降脂治疗的血脂异常患者动脉粥样硬化性心血管疾病一级和二级预防中胆固醇目标达成情况:中国血脂异常防治研究(DYSIS-China)亚组分析]
Zhonghua Xin Xue Guan Bing Za Zhi. 2016 Aug 24;44(8):665-70. doi: 10.3760/cma.j.issn.0253-3758.2016.08.006.
3
Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.降低“极高”ASCVD 风险患者的靶向致动脉粥样硬化脂蛋白胆固醇目标。
Curr Diab Rep. 2019 Nov 21;19(12):146. doi: 10.1007/s11892-019-1246-y.
4
Lipid-lowering therapy and low-density lipoprotein cholesterol goal attainment after acute coronary syndrome: a Danish population-based cohort study.降脂治疗与急性冠状动脉综合征后 LDL-C 目标达标:一项丹麦基于人群的队列研究。
BMC Cardiovasc Disord. 2020 Jul 13;20(1):336. doi: 10.1186/s12872-020-01616-9.
5
Utilization of lipid-modifying therapy and low-density lipoprotein cholesterol goal attainment in patients at high and very-high cardiovascular risk: Real-world evidence from Germany.在高和极高心血管风险患者中使用调脂治疗和降低低密度脂蛋白胆固醇目标达标情况:来自德国的真实世界证据。
Atherosclerosis. 2018 Jan;268:99-107. doi: 10.1016/j.atherosclerosis.2017.11.020. Epub 2017 Nov 20.
6
The Level of Remnant Cholesterol and Implications for Lipid-Lowering Strategy in Hospitalized Patients with Acute Coronary Syndrome in China: Findings from the Improving Care for Cardiovascular Disease in China-Acute Coronary Syndrome Project.中国急性冠状动脉综合征住院患者残余胆固醇水平及其对降脂策略的影响:中国改善心血管疾病护理-急性冠状动脉综合征项目的研究结果
Metabolites. 2022 Sep 24;12(10):898. doi: 10.3390/metabo12100898.
7
[Low-density lipoprotein cholesterol levels and lipid-lowering treatment status among young and middle-aged ultra-high-risk patients with acute coronary syndrome in China].[中国中青年超高危急性冠状动脉综合征患者的低密度脂蛋白胆固醇水平及降脂治疗现状]
Zhonghua Xin Xue Guan Bing Za Zhi. 2022 Dec 24;50(12):1161-1168. doi: 10.3760/cma.j.cn112148-20220920-00731.
8
Vascular Quality of Care Assessment: Clinicians' Adherence to Lipid-Lowering Therapy for Patients with Atherosclerotic Cardiovascular Disease.血管护理质量评估:临床医生对动脉粥样硬化性心血管疾病患者降脂治疗的依从性
Ann Vasc Surg. 2020 Nov;69:197-205. doi: 10.1016/j.avsg.2020.06.003. Epub 2020 Jun 15.
9
Low-Density Lipoprotein Cholesterol Target Attainment in Patients Surviving an Acute Coronary Syndrome in Thailand: Results From the Dyslipidaemia International Study (DYSIS) II.泰国急性冠状动脉综合征存活患者的低密度脂蛋白胆固醇目标达标情况:血脂异常国际研究(DYSIS II)的结果。
Heart Lung Circ. 2020 Mar;29(3):405-413. doi: 10.1016/j.hlc.2019.02.193. Epub 2019 Mar 28.
10
[The expanding needs on lipid-lowering treatment in patients with acute coronary syndrome by applying newly issued definition of extreme high-risk by Chinese Society of Cardiology].[应用中国心脏病学会新发布的极高危定义看急性冠状动脉综合征患者降脂治疗需求的不断增加]
Zhonghua Xin Xue Guan Bing Za Zhi. 2020 Dec 24;48(12):1039-1046. doi: 10.3760/cma.j.cn112148-20200710-00549.

引用本文的文献

1
Optimisation of lipid-lowering therapy post-Acute Coronary Syndromes: a multidisciplinary, cross-interface novel pharmacy care model within a local cardiac rehabilitation centre.急性冠脉综合征后降脂治疗的优化:当地心脏康复中心内的多学科、跨领域新型药学照护模式
J Pharm Policy Pract. 2025 Jul 8;18(1):2523934. doi: 10.1080/20523211.2025.2523934. eCollection 2025.
2
Secondary prevention lipid management following ACS: a missed opportunity?急性冠状动脉综合征后二级预防中的血脂管理:一个被错失的机会?
Br J Cardiol. 2022 Nov 9;29(4):35. doi: 10.5837/bjc.2022.035. eCollection 2022.
3
A Systematic Review of Lipid Management in Secondary Prevention and Comparison of International Lipid Management Pathways.二级预防中血脂管理的系统评价及国际血脂管理路径比较
Cureus. 2023 Feb 25;15(2):e35463. doi: 10.7759/cureus.35463. eCollection 2023 Feb.

本文引用的文献

1
Achievement of European guideline-recommended lipid levels post-percutaneous coronary intervention: A population-level observational cohort study.经皮冠状动脉介入治疗后达到欧洲指南推荐的血脂水平:一项基于人群的观察性队列研究。
Eur J Prev Cardiol. 2021 Jul 23;28(8):854-861. doi: 10.1177/2047487320914115.
2
An Increasing Trend in the Prevalence of Polypharmacy in Sweden: A Nationwide Register-Based Study.瑞典多重用药患病率呈上升趋势:一项基于全国登记数据的研究。
Front Pharmacol. 2020 Mar 18;11:326. doi: 10.3389/fphar.2020.00326. eCollection 2020.
3
Statin dose titration patterns and subsequent major cardiovascular events in very high-risk patients: estimates from Swedish population-based registry data.极高危患者的他汀类药物剂量滴定模式及随后的主要心血管事件:基于瑞典人群注册数据的估计
Eur Heart J Qual Care Clin Outcomes. 2020 Oct 1;6(4):323-331. doi: 10.1093/ehjqcco/qcaa023.
4
Low-density lipoprotein cholesterol target value attainment based on 2019 ESC/EAS guidelines and lipid-lowering therapy titration for patients with acute coronary syndrome.基于2019年欧洲心脏病学会/欧洲动脉粥样硬化学会指南的急性冠状动脉综合征患者低密度脂蛋白胆固醇目标值达标情况及降脂治疗滴定
Eur J Prev Cardiol. 2020 Dec;27(19):2314-2317. doi: 10.1177/2047487319891780. Epub 2019 Dec 9.
5
Early Discontinuation of P2Y Antagonists and Adverse Clinical Events Post-Percutaneous Coronary Intervention: A Hospital and Primary Care Linked Cohort.经皮冠状动脉介入治疗后 P2Y 拮抗剂的早期停药与不良临床事件:医院和初级保健关联队列研究。
J Am Heart Assoc. 2019 Nov 5;8(21):e012812. doi: 10.1161/JAHA.119.012812. Epub 2019 Oct 29.
6
2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.2019年欧洲心脏病学会/欧洲动脉粥样硬化学会血脂异常管理指南:通过血脂修饰降低心血管风险
Eur Heart J. 2020 Jan 1;41(1):111-188. doi: 10.1093/eurheartj/ehz455.
7
Attainment of lipid goals and long-term mortality after coronary-artery bypass surgery.冠状动脉旁路手术后达到血脂目标与长期死亡率。
Eur J Prev Cardiol. 2019 Mar;26(4):401-408. doi: 10.1177/2047487318812962. Epub 2018 Nov 14.
8
Predictors of LDL-cholesterol target value attainment differ in acute and chronic coronary heart disease patients: Results from DYSIS II Europe.急性和慢性冠心病患者 LDL-胆固醇靶值达标情况的预测因素不同:来自 DYSIS II Europe 的结果。
Eur J Prev Cardiol. 2018 Dec;25(18):1966-1976. doi: 10.1177/2047487318806359. Epub 2018 Oct 18.
9
Interpretation of the evidence for the efficacy and safety of statin therapy.他汀类药物治疗疗效和安全性证据解读。
Lancet. 2016 Nov 19;388(10059):2532-2561. doi: 10.1016/S0140-6736(16)31357-5. Epub 2016 Sep 8.
10
Atorvastatin treatment and LDL cholesterol target attainment in patients at very high cardiovascular risk.极高心血管风险患者的阿托伐他汀治疗与低密度脂蛋白胆固醇目标达成情况
Clin Res Cardiol. 2016 Sep;105(9):783-90. doi: 10.1007/s00392-016-0991-z. Epub 2016 Apr 27.

当地心脏康复服务中脂质管理途径的评估。

Evaluation of a lipid management pathway within a local cardiac rehabilitation service.

作者信息

Jones Claire

机构信息

Advanced Practitioner in Cardiac Rehabilitation Cardiac Rehabilitation, Clwydian House, Wrexham Maelor Hospital, Croesnewydd Road, Wrexham, LL13 7TD.

出版信息

Br J Cardiol. 2022 Nov 9;29(4):34. doi: 10.5837/bjc.2022.034. eCollection 2022.

DOI:10.5837/bjc.2022.034
PMID:37332270
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10270301/
Abstract

Elevated cholesterol/lipid levels, especially low-density lipoprotein cholesterol (LDL-C) are known to contribute to the development of atherosclerotic cardiovascular disease (ASCVD). The attainment of lipid targets is known to be suboptimal both globally and locally. This study aimed to evaluate the effectiveness of a lipid management pathway (LMP) in supporting attainment of lipid targets following an acute coronary syndrome (ACS) in a local cohort of cardiac rehabilitation (CR) patients. Quantitative data were retrospectively collected from 54 CR patient records. Local lipid target attainment was benchmarked against national guidelines and pre-pathway implementation audit results. The number of admission lipid profiles increased by 24.8% to 79.6% following implementation of the LMP. There was a 31% improvement in the number of patients achieving either a 50% reduction in LDL-C or an LDL-C level of <1.4 mmol/L. In conclusion, the LMP had a significant positive impact upon the attainment of lipid goals.

摘要

众所周知,胆固醇/血脂水平升高,尤其是低密度脂蛋白胆固醇(LDL-C)会导致动脉粥样硬化性心血管疾病(ASCVD)的发生。在全球和本地,达到血脂目标的情况都不太理想。本研究旨在评估脂质管理途径(LMP)在支持当地心脏康复(CR)患者急性冠状动脉综合征(ACS)后达到血脂目标方面的有效性。从54份CR患者记录中回顾性收集定量数据。将当地血脂目标达成情况与国家指南和途径实施前的审计结果进行对比。实施LMP后,入院血脂检测的次数增加了24.8%,达到79.6%。实现LDL-C降低50%或LDL-C水平<1.4 mmol/L的患者数量提高了31%。总之,LMP对实现血脂目标有显著的积极影响。